Literature DB >> 29571997

Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.

Michael J Baine1, Vivek Verma1, Caitlin A Schonewolf2, Chi Lin1, Charles B Simone3.   

Abstract

BACKGROUND: Contrary to prevailing notions of uniform efficacy regarding stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC), a recent report has indicated increased risk of local failure for squamous cell carcinoma (SCC). As those data have not been corroborated by other studies, we performed a multi-institutional analysis to evaluate the influence of histology on post-SBRT outcomes.
MATERIALS AND METHODS: Records from 152 consecutive patients who received SBRT for primary early-stage NSCLC at two academic medical centers were retrospectively assessed. Primary comparison was between SCC and adenocarcinoma. Patient outcomes including actuarial recurrences and overall survival were calculated using the Kaplan-Meier method. Univariable and multivariable logistic regression analyses addressed associated factors.
RESULTS: At a median follow-up of 44 months, patients with SCC had an increased risk of local, (hazard ratio (HR) (95% confidence interval (CI)): 1.69 (1.05-2.73), p = 0.032), regional (HR (95% CI): 2.03 (1.24-3.33), p = 0.005), and distant failure (HR (95% CI): 1.71 (1.06-2.77), p = 0.036). Median times to local (32 m vs 50m, p = 0.023), regional (26 m vs 50 m, p = 0.011), and distant (26 m vs 50 m, p = 0.024) failure were all significantly reduced in SCC histology. SCC histology was also independently associated with an increased risk for death (HR: 1.80 (1.10-2.94), p = 0.019) and had a 5-yr overall survival of 26%, versus 41% for adenocarcinoma (p = 0.016).
CONCLUSIONS: This multi-institutional analysis corroborates that SCC histology is independently predictive for local, regional, and distant recurrence and worse overall survival. Future data are needed to determine if treatment paradigms should differ by histology for early stage NSCLC.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Histology; Non-small cell lung cancer; Squamous cell carcinoma; Stereotactic body radiation therapy

Mesh:

Year:  2018        PMID: 29571997     DOI: 10.1016/j.lungcan.2018.01.021

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  15 in total

1.  Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer.

Authors:  Nikhil Sebastian; Trudy Wu; Erin Driscoll; Henning Willers; Suzanne Kelly; Hima Bindu Musunuru; Xiaokui Mo; Yubo Tan; Jose Bazan; Karl Haglund; Meng Xu-Welliver; Andrew M Baschnagel; Andrew Ju; Florence Keane; Terence M Williams
Journal:  Radiother Oncol       Date:  2019-06-05       Impact factor: 6.280

2.  An image-based deep learning framework for individualizing radiotherapy dose.

Authors:  Bin Lou; Semihcan Doken; Tingliang Zhuang; Danielle Wingerter; Mishka Gidwani; Nilesh Mistry; Lance Ladic; Ali Kamen; Mohamed E Abazeed
Journal:  Lancet Digit Health       Date:  2019-06-27

Review 3.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 4: systematic review of evidence involving SBRT and ablation.

Authors:  Henry S Park; Frank C Detterbeck; David C Madoff; Brett C Bade; Ulas Kumbasar; Vincent J Mase; Andrew X Li; Justin D Blasberg; Gavitt A Woodard; Whitney S Brandt; Roy H Decker
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

4.  Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.

Authors:  Jingjing Kang; Matthew S Ning; Han Feng; Hongqi Li; Houda Bahig; Eric D Brooks; James W Welsh; Rui Ye; Hongyu Miao; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-10-03       Impact factor: 7.038

5.  Pre-treatment CT imaging in stage IIIA lung cancer: Can we predict local recurrence after definitive chemoradiotherapy?

Authors:  Andrew J Plodkowski; Jose Arimateia Batista Araujo-Filho; Cameron D A Simmers; Jeffrey Girshman; Micheal Raj; Junting Zheng; Andreas Rimner; Michelle S Ginsberg
Journal:  Clin Imaging       Date:  2020-07-17       Impact factor: 1.605

6.  Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.

Authors:  Jessica Karen Wong; Talha Shaikh; Lyudmila DeMora; Eddie Zhang; Hossein Borghaei; Shelly B Hayes; Sameera Kumar; Joshua E Meyer; Mark A Hallman
Journal:  Am J Clin Oncol       Date:  2020-04       Impact factor: 2.787

Review 7.  [Minimally Invasive Therapies for Early Stage Non-small Cell Lung Cancer].

Authors:  Tianyu He; Jinlin Cao; Jinming Xu; Wang Lv; Jian Hu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-02-28

8.  Melittin induces NSCLC apoptosis via inhibition of miR-183.

Authors:  Dongqi Gao; Jingjing Zhang; Lu Bai; Fubo Li; Yi Dong; Qingshan Li
Journal:  Onco Targets Ther       Date:  2018-08-01       Impact factor: 4.147

9.  Time to get started with endobronchial microwave ablation-chances, pitfalls and limits for interventional pulmonologists.

Authors:  Wolfgang Hohenforst-Schmidt; Pavlos Zarogoulidis
Journal:  Transl Lung Cancer Res       Date:  2020-04

10.  Prognostic factors and clinical outcomes after stereotactic radiotherapy for primary lung tumors.

Authors:  Isabel Rodrigues; Tiago Figueiredo; João Gagean; Carolina Ferreira; André Laranja; Tiago Ramos; Sofia Conde; Diana Moreira; Joana Cardia
Journal:  Rep Pract Oncol Radiother       Date:  2020-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.